SomnoMed - Public Comps and Valuation Multiples

SomnoMed Overview

About SomnoMed

SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.

Founded

1987

HQ

Employees

Website

somnomed.com.au

Sectors

Medical Devices

Financials

LTM Revenue $74.5M

LTM EBITDA $6.3M

EV

$98.3M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

SomnoMed Financials

As of August 2025, SomnoMed reported last 12-month revenue of $74.5M and EBITDA of $6.3M.

In the same period, SomnoMed generated $44.4M in LTM gross profit and -$0.4M in net income.

See SomnoMed valuation multiples based on analyst estimates

SomnoMed P&L

In the most recent fiscal year, SomnoMed reported revenue of $60.1M and EBITDA of -$1.7M.

SomnoMed expects next 12-month revenue of XXX and NTM EBITDA of XXX

See SomnoMed valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$74.5M	XXX	$60.1M	XXX	XXX	XXX
Gross Profit	$44.4M	XXX	$36.1M	XXX	XXX	XXX
Gross Margin	60%	XXX	60%	XXX	XXX	XXX
EBITDA	$6.3M	XXX	-$1.7M	XXX	XXX	XXX
EBITDA Margin	8%	XXX	-3%	XXX	XXX	XXX
EBIT	$1.8M	XXX	-$5.5M	XXX	XXX	XXX
EBIT Margin	2%	XXX	-9%	XXX	XXX	XXX
Net Profit	-$0.4M	XXX	-$8.0M	XXX	XXX	XXX
Net Margin	-1%	XXX	-13%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for SomnoMed including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $74.5M. EBITDA for the last twelve months was $6.3M. In the most recent fiscal year, SomnoMed achieved $60.1M in revenue and -$1.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$74.5M	Analyst estimates available to subscribers	$60.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$44.4M	Analyst estimates available to subscribers	$36.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	59.6% gross margin	Analyst estimates available to subscribers	60.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$6.3M	Analyst estimates available to subscribers	-$1.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	8.5% EBITDA margin	Analyst estimates available to subscribers	-2.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$1.8M	Analyst estimates available to subscribers	-$5.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	2.4% EBIT margin	Analyst estimates available to subscribers	-9.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$0.4M	Analyst estimates available to subscribers	-$8.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-0.5% net profit margin	Analyst estimates available to subscribers	-13.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for SomnoMed

This financial data table provides comprehensive performance metrics for SomnoMed, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

SomnoMed generated $74.5M in revenue over the last twelve months.
The company achieved $6.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $44.4M.
Net income over the last twelve months reached -$0.4M.

Fiscal Year Performance

In the most recent fiscal year, SomnoMed reported $60.1M in total revenue.
Fiscal year EBITDA was -$1.7M.
The company maintained a gross profit margin of 60.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was -2.9%.
Net profit margin reached -13.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for SomnoMed. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

SomnoMed Stock Performance

SomnoMed has current market cap of AUD 159M (or $104M), and EV of AUD 150M (or $98.3M).

Market Cap Evolution

SomnoMed Stock Data

As of September 19, 2025, SomnoMed's stock price is AUD 1 (or $0).

See SomnoMed trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$98.3M	$104M	XXX	XXX	XXX	XXX	$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

SomnoMed Valuation Multiples

SomnoMed's trades at 1.7x EV/Revenue multiple, and -133.2x EV/EBITDA.

See valuation multiples for SomnoMed and 15K+ public comps

SomnoMed Financial Valuation Multiples

As of September 19, 2025, SomnoMed has market cap of $104M and EV of $98.3M.

Equity research analysts estimate SomnoMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

SomnoMed has a P/E ratio of -257.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$104M	XXX	$104M	XXX	XXX	XXX
EV (current)	$98.3M	XXX	$98.3M	XXX	XXX	XXX
EV/Revenue	1.3x	XXX	1.7x	XXX	XXX	XXX
EV/EBITDA	15.6x	XXX	-133.2x	XXX	XXX	XXX
EV/EBIT	54.5x	XXX	-24.2x	XXX	XXX	XXX
EV/Gross Profit	2.2x	XXX	n/a	XXX	XXX	XXX
P/E	-257.0x	XXX	-15.7x	XXX	XXX	XXX
EV/FCF	44.4x	XXX	-13.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get SomnoMed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

SomnoMed Margins & Growth Rates

SomnoMed's last 12 month revenue growth is 9%

SomnoMed's revenue per employee in the last FY averaged $15.0M, while opex per employee averaged $10.4M for the same period.

SomnoMed's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

SomnoMed's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for SomnoMed and other 15K+ public comps

SomnoMed Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	9%	XXX	21%	XXX	XXX	XXX
EBITDA Margin	8%	XXX	-1%	XXX	XXX	XXX
EBITDA Growth	24%	XXX	n/a	XXX	XXX	XXX
Rule of 40	8%	XXX	8%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	31%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$15.0M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$10.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	29%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	69%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial